Dolvis Bio Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
as on 05-07-2024
- Paid Up Capital ₹ 0.10 M
as on 05-07-2024
- Company Age 12 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 5.00 M
as on 05-07-2024
- Satisfied Charges ₹ 7.00 M
as on 05-07-2024
- Revenue 1.33%
(FY 2023)
- Profit -1.66%
(FY 2023)
- Ebitda -17.21%
(FY 2023)
- Net Worth 24.67%
(FY 2023)
- Total Assets 3.38%
(FY 2023)
About Dolvis Bio Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹5.00 M. The company has closed loans amounting to ₹7.00 M, as per Ministry of Corporate Affairs (MCA) records.
Sanjay Garg and Anita Garg serve as directors at the Company.
- CIN/LLPIN
U24232CH2012PTC033674
- Company No.
033674
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Mar 2012
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Manimajra, Chandigarh, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Dolvis Bio Pharma Private Limited offer?
Dolvis Bio Pharma Private Limited offers a wide range of products and services, including Pain Relief Drugs & Pharmaceuticals, Muscle Relaxant, Anti Infective Drugs & Medicines, Antibacterial Drugs, Nutraceuticals & Dietary Supplements, Vitamin Tablets & Capsules, Common Disease Medicines, Pharmaceutical Tablets, Psoriasis Ointment, Antibiotic Tablets, Capsule & Syrup.
Who are the key members and board of directors at Dolvis Bio Pharma?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjay Garg  | Director | 27-Mar-2012 | Current |
| Anita Garg | Director | 09-Apr-2019 | Current |
Financial Performance of Dolvis Bio Pharma.
Dolvis Bio Pharma Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 1.33% increase. The company also saw a slight decrease in profitability, with a 1.66% decrease in profit. The company's net worth Soared by an impressive increase of 24.67%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Dolvis Bio Pharma?
In 2023, Dolvis Bio Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Dolphar Life Care Private LimitedActive 6 years 3 monthsSanjay Garg and Anita Garg are mutual person
- Meditech Bio Pharma Private LimitedActive 5 years 2 months
Sanjay Garg and Anita Garg are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 29 Mar 2024 | ₹5.00 M | Open |
Hdfc Bank Limited Creation Date: 06 Aug 2015 | ₹7.00 M | Satisfied |
How Many Employees Work at Dolvis Bio Pharma?
Unlock and access historical data on people associated with Dolvis Bio Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Dolvis Bio Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Dolvis Bio Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
